PolyMedix, Inc. To Present At American Society of Microbiology 109th General Meeting

May 17-21, Philadelphia, PA
RADNOR, Pa.--(Business Wire)--
PolyMedix, Inc. (OTC BB: PYMX, www.polymedix.com), an emerging biotechnology
company developing acute care products for infectious diseases and acute
cardiovascular disorders based on biomimetics, will display a poster at 10:45AM
on Tuesday May 19th at the 109th General Meeting of the American Society of
Microbiology. The poster will describe the latest information on the mechanism
of action of PolyMedix arylamide foldamers.

Titled "Antimicrobial Systemic Antibiotics: Small Molecule Mimics of Host
Defense Proteins," the poster describes the series of arylamide foldamers that
are designed to mimic the activities of naturally occurring antimicrobial
peptides (synthetic small molecule defensin mimetics). These molecules showed
high levels of activity against both Gram-positive and Gram-negative bacteria
with minimal toxicity mammalian cells. The goal of this study was to understand
their mechanism of action and lack of toxicity.

"This research supports the commitment that PolyMedix has to continue to
discover new ways to address life threatening diseases," said Dr. Richard Scott,
Vice President of Research at PolyMedix. "It is the dedication, commitment, and
collaboration with our scientific partners that allows us to continue to explore
molecules that could be effective against other infections. It is a wonderful
opportunity to present these findings in Philadelphia at the ASM General
Meeting."

PolyMedix`s lead defensin-mimetic antibiotic compound is PMX-30063, currently in
Phase I clinical development. On December 10, 2008, PolyMedix announced the
results of the first Phase I human clinical study with PMX-30063. The results of
that study suggest that it should be possible to achieve clinically therapeutic
levels with daily doses of PMX-30063 which are lower than those associated with
any adverse effects seen in the single dose study. The initial indication
planned for PMX-30063 is as a treatment for pan-Staphylococcal infections,
including MRSA (methicillin-resistant Staphylococcus aureus).

Meeting Summary of the ASM General Meeting

The General Meeting program provides interest sessions on areas of Policy,
Education, History, Communications, International Affairs, Minority Affairs,
Women`s Affairs, Career Development, and the Academy. Details on specific
sessions may be seen through the home webpage: http://www.gm.asm.org

About PolyMedix, Inc.

PolyMedix is a publicly traded biotechnology company focused on the development
of novel drugs and biomaterials for the treatment of infectious diseases and
acute cardiovascular disorders. PolyMedix`s compounds are based on biomimetics:
non-peptide small molecule drug candidates that mimic the activity of proteins.
The Company`s antibiotic compounds, including PMX-30063 - small molecule
mimetics of human host-defense proteins - have a mechanism of action distinct
from those of current antibiotic drugs, a mechanism which is intended to make
bacterial resistance unlikely to develop. The Company`s goal is to develop these
as rapidly acting antibiotics for serious systemic and local infections. The
Company plans to continue the development of polymeric formulations as
antimicrobial biomaterials, which can be used as additives to paints, plastics,
and textiles to create self-sterilizing products and surfaces. The Company`s
heptagonist compounds, including PMX-60056, reverse the activity of both heparin
and Low Molecular Weight Heparins, with the goal of developing an antagonist
drug that is safer and easier to use than currently approved therapy. For more
information, please visit PolyMedix on its website at www.polymedix.com.

This press release contains forward-looking statements made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995 that
involve risks and that could cause PolyMedix`s actual results and experience to
differ materially from anticipated results and expectations expressed in these
forward looking statements. PolyMedix has in some cases identified
forward-looking statements by using words such as "anticipates," "believes,"
"hopes," "estimates," "looks," "expects," "plans," "intends", "goal",
"potential," "may", and similar expressions. Among other things, there can be no
assurance that PolyMedix`s compounds will enter or successfully complete
clinical testing or be granted regulatory approval to be sold and marketed in
the Unites States or elsewhere. A more complete description of these risks,
uncertainties and assumptions is included in PolyMedix`s filings with the
Securities and Exchange Commission. You should not place undue reliance on any
forward-looking statements. PolyMedix undertakes no obligation to release
publicly the results of any revisions to any such forward-looking statements
that may be made to reflect events or circumstances after the date of this press
release or to reflect the occurrence of unanticipated events, except as required
by applicable law or regulation.

PolyMedix, Inc.
Lona Cornish, 484-598-2340
lcornish@polymedix.com
or
The Investor Relations Group
Investors:
Erika Moran, 212-825-3210
emoran@investorrelationsgroup.com
or
Media:
Janet Vasquez, 212-825-3210
jvasquez@investorrelationsgroup.com

Copyright Business Wire 2009